Reagent | Fructosamine (Glycated Protein)
Offering Improved Specialty and Reliability
Benefits of the Fructosamine Assay
The Randox enzymatic method offers improved specificity and reliability compared to the conventional NBT-based methods as the enzymatic method does not suffer from non-specific interferences unlike the existing methods which can also be time-consuming and difficult to automate.
Standardisation to the highest level
The Randox dedicated fructosamine calibrator and controls are assigned relative to human serum glycated with 14-C glucose, directly reflecting the nature of the patient sample.
A correlation coefficient of r=0.98 was displayed with the Randox fructosamine assay was compared to commercially available methods.
Excellent measuring range
The Randox fructosamine assay has a measuring range of 8.12 – 18033µmol/l for the comfortable detection of clinically important results.
The Randox fructosamine assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Applications available detailing instrument-specific settings for the convenient use of the Randox fructosamine assay on a variety of clinical chemistry analysers.
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
Fructosamine (glycated protein) has been identified as an early indicator of diabetic control compared to other markers such as HbA1c. RBCs live for approximately 120 days, HbA1c represents the average blood glucose levels for the previous 2 to 3 months. Conversely, fructosamine has a shorter lifespan, of about 14 to 21 days, reflecting average blood glucose levels from the previous 2 to 3 weeks 1.
Fructosamine testing has been identified as being the best for patient care as HbA1c results can be inconclusive for several reasons. Genetic, haematological and disease-related factors negatively impact HbA1c levels, with low levels observed in late stage chronic kidney disease, conditions that shorten the lifespan of erythrocytes such as haemolytic anaemia, and in certain haemoglobinopathies such as sickle cell disease 2.
In gestational diabetes, fructosamine should be tested as HbA1c levels are difficult to interpret as HbA1c integrates glycaemia over the lifespan of the erythrocyte. Therefore, HbA1c is relatively insensitive to short term changes. Consequently, HbA1c testing isn’t suitable in the monitoring of the effects of changes in medication. Fructosamine is a medium-term marker (shorter life span) and is a much more suitable test 2.
In a diabetic patient where blood glucose levels are abnormally elevated, the concentration levels of fructosamine also increase as fructosamine is formed by a non-enzymatic Maillard reaction between glucose and amino acid residues of proteins. During this glycation process, an intermediate labile Schiff base is produced which is converted to a more stable ketoamine (fructosamine) via an Amadori rearrangement 3.
The Fasting Plasma Glucose (FPG) test measures the level of blood sugars which is used to diagnose and monitor diabetes based on insulin function. The main drawback of this test is that a hormone called glucagon, produced in the pancreas, is triggered during prolonged fasting, signalling the liver to release glucose into the bloodstream. In diabetic conditions, either the body is unable to generate enough insulin or cannot appropriately respond to insulin. Consequently, FPG levels remain high 1.
In the1980’s, HbA1c was incorporated into clinical practice as HbA1c levels correlated well with glycaemic control over a 2 to 3-month period. The main drawback of this test is that any condition that reduces the survival rate of erythrocytes such as haemolytic anaemia will falsely lower the HbA1c test results regardless of the assay method utilised 3.
Clinical Chemistry EQA
 Gounden V, Jialal I. Treasure Island, FL: StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK470185/ (accessed 28 February 2020).
 Kilpatrick ES, Atkin SL. Using haemoglobin A1c to diagnose type 2 diabetes or to identify people at high risk of diabetes. BMJ 2014; 348: https://www.bmj.com/content/348/bmj.g2867 (accessed 28 February 2020).